Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination.
asia
drug resistance
epidemiology
genetic surveillance
global health
infectious disease
malaria
microbiology
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
10 08 2021
10 08 2021
Historique:
received:
10
09
2020
accepted:
30
06
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
9
10
2021
Statut:
epublish
Résumé
National Malaria Control Programmes (NMCPs) currently make limited use of parasite genetic data. We have developed GenRe-Mekong, a platform for genetic surveillance of malaria in the Greater Mekong Subregion (GMS) that enables NMCPs to implement large-scale surveillance projects by integrating simple sample collection procedures in routine public health procedures. Samples from symptomatic patients are processed by SpotMalaria, a high-throughput system that produces a comprehensive set of genotypes comprising several drug resistance markers, species markers and a genomic barcode. GenRe-Mekong delivers Genetic Report Cards, a compendium of genotypes and phenotype predictions used to map prevalence of resistance to multiple drugs. GenRe-Mekong has worked with NMCPs and research projects in eight countries, processing 9623 samples from clinical cases. Monitoring resistance markers has been valuable for tracking the rapid spread of parasites resistant to the dihydroartemisinin-piperaquine combination therapy. In Vietnam and Laos, GenRe-Mekong data have provided novel knowledge about the spread of these resistant strains into previously unaffected provinces, informing decision-making by NMCPs. GenRe-Mekong provides detailed knowledge about drug resistance at a local level, and facilitates data sharing at a regional level, enabling cross-border resistance monitoring and providing the public health community with valuable insights. The project provides a rich open data resource to benefit the entire malaria community. The GenRe-Mekong project is funded by the Bill and Melinda Gates Foundation (OPP11188166, OPP1204268). Genotyping and sequencing were funded by the Wellcome Trust (098051, 206194, 203141, 090770, 204911, 106698/B/14/Z) and Medical Research Council (G0600718). A proportion of samples were collected with the support of the UK Department for International Development (201900, M006212), and Intramural Research Program of the National Institute of Allergy and Infectious Diseases.
Sections du résumé
Background
National Malaria Control Programmes (NMCPs) currently make limited use of parasite genetic data. We have developed GenRe-Mekong, a platform for genetic surveillance of malaria in the Greater Mekong Subregion (GMS) that enables NMCPs to implement large-scale surveillance projects by integrating simple sample collection procedures in routine public health procedures.
Methods
Samples from symptomatic patients are processed by SpotMalaria, a high-throughput system that produces a comprehensive set of genotypes comprising several drug resistance markers, species markers and a genomic barcode. GenRe-Mekong delivers Genetic Report Cards, a compendium of genotypes and phenotype predictions used to map prevalence of resistance to multiple drugs.
Results
GenRe-Mekong has worked with NMCPs and research projects in eight countries, processing 9623 samples from clinical cases. Monitoring resistance markers has been valuable for tracking the rapid spread of parasites resistant to the dihydroartemisinin-piperaquine combination therapy. In Vietnam and Laos, GenRe-Mekong data have provided novel knowledge about the spread of these resistant strains into previously unaffected provinces, informing decision-making by NMCPs.
Conclusions
GenRe-Mekong provides detailed knowledge about drug resistance at a local level, and facilitates data sharing at a regional level, enabling cross-border resistance monitoring and providing the public health community with valuable insights. The project provides a rich open data resource to benefit the entire malaria community.
Funding
The GenRe-Mekong project is funded by the Bill and Melinda Gates Foundation (OPP11188166, OPP1204268). Genotyping and sequencing were funded by the Wellcome Trust (098051, 206194, 203141, 090770, 204911, 106698/B/14/Z) and Medical Research Council (G0600718). A proportion of samples were collected with the support of the UK Department for International Development (201900, M006212), and Intramural Research Program of the National Institute of Allergy and Infectious Diseases.
Identifiants
pubmed: 34372970
doi: 10.7554/eLife.62997
pii: 62997
pmc: PMC8354633
doi:
pii:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G0600718
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098051
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090770
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006212/1
Pays : United Kingdom
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Wellcome Trust
ID : 201900
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106698/B/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203141
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911/Z/16/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
CJ, NT, MM, RM, HQ, BH, VV, TN, HR, Rv, Lv, RF, FN, MH, NP, SG, PR, KC, PN, EA, SP, RM, RL, CH, LD, KN, TN, TH, AS, DU, CB, CF, MO, TP, RT, CA, AM, GD, JL, DP, NC, DL, SS, JC, PJ, BH, SP, AP, FS, KL, MT, TH, PS, SS, PB, AT, SB, NV, AA, AU, AF, CK, ED, MK, MA, KL, SR, AJ, KR, CH, MD, RV, NK, PW, JA, RP, CA, TC, CM, TN, JS, BJ, JK, KJ, DM, XC, JS, RA, VS, SG, KR, ND, AD, DK, OM No competing interests declared, HN, NZ, SC is an employee of Vysnova Partners Inc
Références
Malar J. 2016 Dec 20;15(1):597
pubmed: 27998271
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
J Infect Dis. 2011 Dec 15;204(12):1980-8
pubmed: 22021623
Elife. 2019 Apr 02;8:
pubmed: 30938289
Trans R Soc Trop Med Hyg. 2000 Mar-Apr;94(2):113-27
pubmed: 10897348
Trans R Soc Trop Med Hyg. 2009 Apr;103 Suppl 1:S11-4
pubmed: 19084883
Parasitol Int. 2009 Sep;58(3):201-9
pubmed: 19393762
Science. 2004 Aug 20;305(5687):1124
pubmed: 15326348
J Infect Dis. 2015 Mar 1;211(5):670-9
pubmed: 25180241
Trends Parasitol. 2009 Dec;25(12):557-63
pubmed: 19864183
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Nat Genet. 2013 Jun;45(6):648-55
pubmed: 23624527
Nat Genet. 2015 Mar;47(3):226-34
pubmed: 25599401
Lancet Infect Dis. 2019 Sep;19(9):943-951
pubmed: 31345709
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Antimicrob Agents Chemother. 2013 Nov;57(11):5277-83
pubmed: 23939897
N Engl J Med. 2008 Dec 11;359(24):2619-20
pubmed: 19064625
Science. 2016 Aug 19;353(6301):731
pubmed: 27540141
C R Acad Sci III. 1998 Aug;321(8):689-97
pubmed: 9769862
Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26
pubmed: 26014949
Lancet Infect Dis. 2020 Jan;20(1):e20-e25
pubmed: 31540841
Wellcome Open Res. 2021 Feb 24;6:42
pubmed: 33824913
Front Genet. 2019 Mar 22;10:241
pubmed: 30967898
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Lancet Infect Dis. 2018 Mar;18(3):337-345
pubmed: 29398391
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):7067-72
pubmed: 25941365
Elife. 2016 Mar 04;5:
pubmed: 26943619
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
PLoS Med. 2019 Feb 15;16(2):e1002745
pubmed: 30768615
J Infect Dis. 2015 Sep 1;212(5):694-701
pubmed: 25672905
N Engl J Med. 2006 Nov 9;355(19):1959-66
pubmed: 17093247
Wellcome Open Res. 2018 Aug 31;3:109
pubmed: 31206035
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Lancet. 2018 May 12;391(10133):1916-1926
pubmed: 29703425
J Infect Dis. 2014 Oct 1;210(7):1110-4
pubmed: 24723474
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Lancet Infect Dis. 2015 Jun;15(6):683-91
pubmed: 25877962
Acta Trop. 2012 Mar;121(3):227-39
pubmed: 21382335